Agilent Technologies Inc. has acquired Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.   The acquisition complements Agilent’s SureSelect portfolio and further augments Agilent’s strategy to expand into the high-growth clinical research and diagnostics markets. The chemistries and assays from Avida Biomed are comp...